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ABSTRACT
The cryopreservation of ovarian tissue with subsequent trans-
plantation of the tissue represents an established method of
fertility protection for female patients who have to undergo
gonadotoxic therapy. The procedure can be performed at
any point in the cycle and thus generally does not lead to any
delay in oncological therapy. With the aid of this procedure,
more than 130 births to date worldwide have been able to be
recorded. The birth rate is currently approximately 30% and it
can be assumed that this will increase through the further op-
timisation of the cryopreservation and surgical technique.* Equal authorship
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The concept paper presented here is intended to provide
guidance for managing cryopreservation and transplantation
of ovarian tissue to German-speaking reproductive medicine
centres.
ZUSAMMENFASSUNG
Die Kryokonservierung von Ovarialgewebe mit anschließender
Transplantation des Gewebes stellt eine etablierte Methode
der Fertilitätsprotektion für Patientinnen dar, die sich einer go-
nadotoxischen Therapie unterziehen müssen. Das Verfahren
kann zu jedem Zykluszeitpunkt erfolgen und führt somit meis-
tens zu keiner Verzögerung der onkologischen Therapie. Mit-
hilfe dieses Verfahrens konnten bis dato mehr als 130 Gebur-
ten weltweit verzeichnet werden. Die Geburtenrate beträgt
derzeit ca. 30% und es ist von einer Steigerung durch eine wei-
tere Optimierung der Kryokonservierungs- und Operations-
technik auszugehen. Das hier vorgelegte Konzeptpapier soll
Handlungsempfehlungen für den Umgangmit der Kryokonser-
vierung und Transplantation von Ovarialgewebe an deutsch-
sprachigen reproduktionsmedizinischen Zentren geben.
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Based on advancements in systemic drug (chemotherapy, tar-
geted therapy) and locoregional therapy (surgery, radiation ther-
apy), the survival rate in malignant and non-malignant diseases
has significantly improved. However, the treatments frequently
lead to a partial or complete impairment of gonad function with
possible germ cell loss. Therefore it is important to counsel female
patients prior to gonadotoxic therapy with regard to preserving
their fertility. By now, there are a number of fertility-protecting
techniques which offer a realistic chance of a later pregnancy. In
addition to gonadal transposition prior to radiotherapy, drug-
based gonad protection using GnRH analogues and cryopreserva-
tion of fertilised and unfertilised oocytes, the removal and cryo-
preservation of ovarian tissue represents a promising option for
girls and women [1–3].
The cryopreservation of ovarian tissue with subsequent trans-
plantation is a method of fertility preservation which can be per-
formed very shortly before cytotoxic therapy. It can take place at
any point in the cycle and thus generally does not lead to any delay
in oncological therapy [4,5]. Since the first births following ovarian
tissue transplantation in 2004 worldwide [6] and in 2011 in Ger-
many [7], themethod has been increasingly used in routine clinical
practice. In the FertiPROTEKT network (Germany, Austria and Swit-
zerland), 163 transplantations were performed in 126 women by
January 2018 [8]. The figures from Germany are comparable with
the successes internationally. In total, there have been more than
130 births following orthotopic transplantation of cryopreserved
ovarian tissue to date worldwide [8–12]. The birth rate is currently
approximately 30–35% and it can be assumed that this will in-
crease further through optimisation of cryopreservation and sur-
gical technique [13]. The transplantation of cryopreserved ovarian
tissue is thus an established option for fertility protection for on-
cological patients [14–16].
The concept paper presented here is intended to provide rec-
ommendations for action for the removal, transport, cryopreser-
vation and transplantation of ovarian tissue in German-speaking
reproductive medical centres and thus at centres of the FertiPRO-
TEKT network. This is to ensure the quality of the cryopreserva-
tion and transplantation of ovarian tissue at the individual centres
with the objective of offering an optimal and consistent standard.
These are not recommendations in the sense of a guideline but
rather a joint decision by leading experts on the subjects of re-
moval, cryopreservation and transplantation of ovarian tissue.54For this reason, the nomenclature does not correspond to the rec-
ommendation classifications of a guideline.Removal of Ovarian Tissue
Fromwhom and up to which age should ovarian tissue
be removed?
The chances for a later pregnancy are greater the higher the ovar-
ian reserve is, that is, the follicular density in the cryopreserved
and transplanted ovarian tissue [17,18]. The Edinburgh criteria in-
dicate an age limit of 35 years [19], while other international pub-
lications mention a maximum age of 40 years [20]. In a publica-
tion by van der Ven et al., the pregnancy rates following transplan-
tation of ovarian tissue were 33% in women who were under age
35 at the time of cryopreservation, in comparison to 18% in wom-
en who were over age 35 at the time of cryopreservation. In wom-
en over age 40, no pregnancy was able to be achieved [8].
The cryopreservation of ovarian tissue can also be performed
on pre- and peripubertal girls [21]. There are case reports indicat-
ing that an induction of puberty can be achieved through the
transplantation of prepubertal ovarian tissue [22,23]. In addition,
there is a case report of a birth following transplantation of cryo-
preserved premenarchal tissue [24]. This shows that transplanta-
tion following prepubertal cryopreservation of ovarian tissue can
lead to pregnancies. However, in this regard, it must be borne in
mind that the patient was already 13 years old with the onset of
thelarche at the time the tissue was removed [24]. In addition,
there is a press release of a birth following transplantation of ovar-
ian tissue which had been cryopreserved prior to menarche at the
age of 9 years [25]. The indication for cryopreservation of ovarian
tissue in pre- and peripubertal girls is currently still unclear and re-
quires an individual assessment of the type of therapy and also of
the gonadotoxic dose [1].
JOINT DECISION
The cryopreservation of ovarian tissue should be performed
prior to the start of gonadotoxic therapy in girls and women
only up to the age of 40 years. Ovarian cryopreservation can
also be considered on a case-by-case basis in prepubertal
girls, taking the gonadotoxic therapy and the risks of the sur-
gical procedure into account.Beckmann MW et al. Concept Paper on… Geburtsh Frauenheilk 2019; 79: 53–62
▶ Table 1 Ovariotoxic effect of various chemotherapeutic agents
[1].
Risk Regimen/substance
High risk
(> 80% risk of
permanent
amenorrhoea)
▪ CMF, CEF, CAF, TAC × 6 in women ≥ 40 years
▪ Conditioning for stem cell transplantation
(particularly alkylating-agent-based
myeloablative conditioning with busulfan,
cyclophosphamide, melphalan)
▪ BEACOPP × 6–8 in women > 35 years
Intermediate risk
(40–60% risk of
permanent
amenorrhoea)
▪ CMF, CEF, CAF, TAC × 6 in women
30–39 years
▪ AC × 4 in women ≥ 40 years
▪ AC or EC × 4→ taxane
▪ BEACOPP × 6–8 in women 25–35 years
▪ CHOP × 6 in women ≥ 35 years
▪ Therapy typical for bone and soft tissue
sarcomas
Low risk
(< 20% risk of
permanent
amenorrhoea)
▪ CMF, CEF, CAF, TAC × 6 in women ≤ 30 years
▪ AC × 4 in women ≤ 40 years
▪ BEACOPP × 6–8 in women < 25 years
▪ ABVD × 2–4
▪ CHOP × 6 in women < 35 years
▪ CVP
▪ Therapy typical for AML (anthracycline/
cytarabine)
▪ Therapy typical for ALL (multi-agent)
▪ FOLFOX in women ≤ 40 years
Very low or
no risk of
permanent
amenorrhoea
▪ Methotrexate
▪ Fluorouracil
▪ Vincristine
▶ Table 2 Gonadotoxicity in the case of radiation of the ovary and
risk of ovarian insufficiency (modified according to [26]).
Effective sterilising dose (ESD) Ovarian radiation dose (Gy)
No relevant effects 0.6
No relevant effects at < 40 years 1.5
0 years 20.3
10 years 18.4
20 years 16.5
30 years 14.3
40 years 6On which chemotherapy and from which level
of risk for premature ovarian insufficiency (POI)
should ovarian tissue be removed?
The cryopreservation of ovarian tissue is recommended for wom-
en in whom the preservation of ovarian function is directly or indi-
rectly threatened due to an underlying oncological, haematologi-
cal, or other illness [4]. This particularly applies in the case of up-
coming gonadotoxic chemotherapy or radiation in the lesser pel-
vis.
The removal and cryopreservation of ovarian tissue should in
particular be offered to all women with a high and intermediate
risk of premature ovarian insufficiency (POI). However, even in
women with a low risk of permanent amenorrhea, this option
should be discussed with the patient. In doing so, it should be tak-
en into account that a risk of POI of ≤ 20% means that one out of
every five women who receives one of these chemotherapy regi-
mens is at risk of suffering POI. The ovariotoxic effect of various
chemotherapeutic agents and radiation can be found in the tables
(▶ Tables 1 and 2) of the S2k guideline “Fertility preservation in
oncological therapies” [1].
JOINT DECISION
The cryopreservation of ovarian tissue should be offered
when there is a high or intermediate risk and – on a case-by-
case basis – also when there is a low risk of premature ovarian
insufficiency due to gonadotoxic therapy.
How should the tissue be removed?
The gold standard for the removal of ovarian tissue is laparoscopy.
A laparotomy should only be performed if this is necessary within
the scope of the underlying oncological diseases. In the case of re-
moval of ovarian tissue, chromopertubation should be performed
under certain conditions (see ▶ Fig. 1). If unilateral tubal occlu-
sion is seen, the ovarian tissue should be taken on this side in or-
der to preserve the potentially still functioning ovarian tissue on
the side with the patent tube. If no POI occurs, an optimal site is
available there later for a transplantation. However, it should pref-
erably be ensured that ovarian tissue is not taken on the side of a
corpus luteum or a preovulatory follicle or in the case of existing
ovarian cysts, since the follicular density of the ovarian tissue to be
cryopreserved may be limited here and the cortex quality in any
case.
The ovarian tissue should be detached using scissors without
electrical coagulation [27–29]. Haemostasis of the wound sur-
face should be performed on the remaining ovary without form-
ing additional areas of necrosis. There are no evidence-based
studies available on the various techniques (coagulation, sutures)
(▶ Fig. 2).
The surgical risks of removing ovarian tissue are low [27–29].
There is an increased risk of infections and bleeding which is only
dependent on the oncological disease. The removal of ovarian tis-
sue is anticipated to involve one complication per 500 laparosco-
pies which necessitates surgical revision [30].
A histological examination of a reference sample of the ovarian
tissue taken to rule out malignant cells and to identify follicles (aBeckmann MW et al. Concept Paper on… Geburtsh Frauenheilk 2019; 79: 53–62tissue fragment from the ovarian tissue taken measuring at least
2 × 2mm) should be performed and documented by the centre
at which the ovarian tissue was removed. The risks of ovarian me-
tastasis and the resultant consequences can be found in the S2k
guideline “Fertility preservation in oncological diseases” [1].55
Cyst?
Follicle?
Corpus luteum?
Unilaterally?None?
Bilaterally?
Contralateral
removal
Chromopertubation
Bilaterally occluded?Unilaterally occluded?Bilaterally patent?
Removal on
left
Removal on
occluded side
Removal on
left
▶ Fig. 1 Algorithm for the removal of ovarian tissue.
▶ Fig. 2 Removal of ovarian tissue via laparoscopy (photo from Department of Obstetrics and Gynaecology, Erlangen).
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▪ The gold standard for the removal of ovarian tissue is lapa-
roscopy.
▪ A laparotomy should only be performed if this is necessary
within the scope of the underlying oncological disease.
▪ The ovarian tissue should be detached using scissors and
sources of bleeding should only be coagulated in a tar-
geted manner afterwards (punctate coagulation).
▪ Histology to rule out malignant cells in the ovarian tissue
(at least 2 × 2mm) must be performed by the centre at
which the ovarian tissue was removed.56How much ovarian tissue should be taken?
At least ½ to 2⁄3 of the ovary should be taken antimesenterically
[27–29] (▶ Fig. 2). Bilateral removal at the ovaries should be con-
sidered to be an exception (for example, in the case of bilateral
ovarian cysts). Due to the small amount of material, biopsies
should not be performed [27–29]. However, the patient should
also be informed of the possibility for a unilateral ovariectomy,
particularly in the case of a high risk of POI. Data show that after
a unilateral ovariectomy, menopause can occur approximately
one year earlier [31].Beckmann MW et al. Concept Paper on… Geburtsh Frauenheilk 2019; 79: 53–62
JOINT DECISION
At least ½ to 2⁄3 of an ovary (preferably without ovarian pa-
thologies) should be removed. Bilateral removal should be
performed only in exceptional cases. Biopsies are not recom-
mended.Transport of Ovarian Tissue
How and at which temperature should
ovarian tissue be transported after removal
and prior to cryopreservation?
Those facilities which do not have possibilities for performing
cryopreservation of ovarian tissue themselves can send the ovar-
ian tissue for tissue processing to specialised centres with an affili-
ated cryobank [32].
For most organ and tissue transport (for example, kidney, liv-
er), low temperatures are generally selected. The data regarding
the transport of ovarian tissue are limited. In the few investiga-
tions conducted, the transport temperature varied between 4–
37 °C (10–13). Most studies show that the best conditions are
found in the case of low temperatures, around 4 °C. Low temper-
atures ensure that the cellular metabolism is decreased in the cor-
responding tissue/organ. In this connection, the need for and, at
the same time, the consumption of oxygen are also reduced.
There are suitable transport contains with special pairs of cold
packs for the transport of ovarian tissue. The transport container
ensures continuous cooling of the tissue during transport at 4 °C
and is provided by the respective cryobank (▶ Fig. 3).
JOINT DECISION
Prior to cryopreservation, ovarian tissue should be trans-
ported chilled (4–8 °C) in special transport containers.
How long can ovarian tissue be transported
prior to cryopreservation (transport period)?
The transport box can be shipped during the day via daytime cou-
rier service or overnight via express courier service. The maximum
transport time of the tissue without a significant loss of follicles
anticipated is currently not yet sufficiently proven. Investigations
show that hypothermia of the ovarian tissue during various trans-
port periods can last up to 24 hours without lasting damage to the
follicular reserve [33–36].
JOINT DECISION
The transport of ovarian tissue up to 24 hours prior to cryo-
preservation is possible.Beckmann MW et al. Concept Paper on… Geburtsh Frauenheilk 2019; 79: 53–62Which transport medium should be used?
Various transport media are described by different working
groups in the literature [35–38]. There are no adequate investiga-
tions which show which transport medium is most suitable. In the
case of organ and tissue transplants, Custodiol® is a certified and
approved medium which must be used under chilled conditions
(4–8 °C) [39].
JOINT DECISION
Custodiol® or a comparable medium should be used under
chilled conditions (4–8 °C) as a transport medium.Cryopreservation of Ovarian Tissue
Slow freezing vs. vitrification?
In general, two freezing techniques are used in reproductive med-
icine: the slow freezing method, a cryopreservation method with
equilibration, and vitrification, a freezing method without equili-
bration [32]. Both methods are used worldwide in the cryopreser-
vation of ovarian tissue. In routine practice, because of the better
pool of data available, the slow-freezing method is currently rec-
ommended [1,5, 40]. Apart from two published births following
transplantation of vitrified ovarian tissue, the tissue in the case of
all other births was slowly frozen [41,42]. The future significance
of vitrification cannot yet be estimated due to the current data
and validations are needed for universal clinical use [43].
Slow freezing with cooling rates of 0.3 °C/min requires the use
of freezers. In a computer-controlled slow-freezing method, the
samples are cooled down according to a modified programme
[44] such that they can subsequently be stored indefinitely in a ni-
trogen gas phase (at −190 °C). Clear identification of the stored
samples must be ensured, for example, through the use of the sin-
gle European code or a comparable coding system.
JOINT DECISION
Based on the better pool of data available, ovarian tissue
should at present be cryopreserved in routine practice with
the established slow-freezing method.
How should the ovarian tissue be processed?
According to the standards of an IVF laboratory, a suitable room
with a sterile class II laminar air flow unit in which surgical prepa-
ration can take place should be available for processing the ovar-
ian tissue prior to freezing. In the case of chilled preparation, the
ovarian medulla is to be carefully dissected away from the ovarian
cortex and in doing so, a thin portion of residual stroma should be
left to ensure that there is an optimal starting point for neovascu-
larisation of the transplants later [43]. Depending on the size and
quality, pieces of ovarian tissue measuring 3 × 2 × 1mm up to a
maximum of 4 × 8 × 1mm should be cut from the prepared cortex
(▶ Fig. 4). The size of the pieces should be listed in the transplan-
tation record.57
▶ Fig. 3 Transport container for ovarian tissue. ▶ Fig. 4 Cut ovarian tissue pieces.
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▪ The ovarian tissue should be processed in a suitable room
under a sterile class II laminar air flow.
▪ The ovarian tissue pieces should measure between
3 × 2 × 1mm up to a maximum of 4 × 8 × 1mm. The size
of the ovarian tissue pieces should be listed in the trans-
plantation record.
Which freezing medium should be used?
The choice of the cryoprotective used is an important point which
is largely responsible for whether cryopreservation is successful.
Glycerine, ethylene glycol, DMSO and propanediol in combination
with corresponding carrier media and a protein supplement are
available for this [34,36,45,46]. Using the cryoprotectives ethyl-
ene glycol, propanediol or DMSO, similarly good survival rates of
the germ cells as well as intact tissue morphologies and cell struc-
tures are demonstrated following cryopreservation and subse-
quent thawing; glycerine performed the worst in investigations
[34,36,45,46]. Internationally, DMSO is the most frequently used
and best established cryoprotective for ovarian tissue [41,47,48].
JOINT DECISION
DMSO or, alternatively, ethylene glycol can be used as a cryo-
protective.
Vitality testing of the ovarian tissue?
The prepared ovarian tissue is examined for quality assurance pri-
or to cryopreservation and also during preparation for a trans-
plantation in the case of premature ovarian failure following cyto-
toxic therapy. The examinations ensure that the removal of the
tissue, its transport/processing and also the cryopreservation and
thawing have not led to any relevant damage to the tissue – like-
wise, a possible cortex potential (number of primordial follicles in
a particular area) of each patient is individually determined.58Small, standardised biopsy punches from various peripheral
areas are methodically produced for this as part of the prepara-
tion of the ovarian tissue taken; following tissue digestion and cal-
cein-acetoxymethyl ester staining or a live-dead assay, these
punches are analysed for the number of vital primordial follicles.
The concentration of vital primordial follicles and the anti-Müller
hormone level in the serum, the antral follicle count and the age
of the patient (all determined at the time that the ovarian tissue is
removed or before the start of cytotoxic therapy) are considered
to be parameters for determining the fertility reserve – but also
for later determination of the number of ovarian cortex pieces to
be transplanted.
For the validation of a facility which processes ovarian tissue,
the FertiPROTEKT network recommends that cryopreserving
centres have their freezing technique checked through a xeno-
transplantation of ovarian tissue on immunodeficient severe-
combined-immunodeficiency (SCID) mice before offering cryo-
preservation of ovarian tissue in routine clinical practice. This is
able to show that the follicles have a qualitative development po-
tential/follicular growth following cryopreservation and thawing.
JOINT DECISION
Vitality testing with a suitable assay should be performed
before freezing and before transplantation.Transplantation of Ovarian Tissue
When should ovarian tissue be transplanted
and up to which age?
Transplantation of ovarian tissue should take place after success-
ful oncological therapy in female patients with a manifest desire
for a child and in the case of failure of ovarian function, for the re-
sumption of folliculogenesis and to lead to a pregnancy [49]. A
transplantation can be considered even in patients who still have
a regular cycle but limited ovarian reserve. Transplantation to re-Beckmann MW et al. Concept Paper on… Geburtsh Frauenheilk 2019; 79: 53–62
▶ Fig. 5 Orthotopic transplantation of ovarian tissue in a peritoneal pocket of the pelvic peritoneum of the ovarian fossa.store longstanding ovarian function which would, where applica-
ble, replace necessary hormone replacement therapy should not
be primarily recommended due to the limited activity of the
transplanted tissue [50]. Prior to transplantation, especially if
there is no POI and nevertheless a transplantation is being consid-
ered, the couple should undergo a basic clarification of causes of
infertility to rule out or correct other causes of infertility or this
should be included in the further treatment planning.
The age of 45 years should not be exceeded as an age limit for
a transplantation [51]. If a transplantation is to be recommended
at the earliest following oncological treatment, this should be de-
termined depending on the underlying oncological disease and
individually together with the attending oncologists, taking the
age of the patient and the oncological prognosis into account.
JOINT DECISION
▪ Transplantation of ovarian tissue should be performed in
women with a manifest desire for a child and failure of
ovarian function (amenorrhoea/oligomenorrhoea), up to
the age of 45 years.
▪ A basic clarification of causes of infertility should be per-
formed prior to transplantation.Beckmann MW et al. Concept Paper on… Geburtsh Frauenheilk 2019; 79: 53–62How should the ovarian tissue be transplanted
(surgical technique and site of transplantation)?
The transplantation of ovarian tissue is generally performed via
laparoscopy [27–29]. In routine clinical practice, orthotopic
transplantation is primarily used. In an orthotopic transplantation,
the ovarian tissue is transplanted either in the pelvic wall caudo-
dorsal to the ovaries or in/on the ovary. Internationally, various or-
thotopic transplantation techniques are described [27–29]. It is
still unclear which of the techniques and which locations lead to
the greatest chances for pregnancy.
The better circulation in the pelvic wall and the easier surgical
feasibility (and the associated low surgical risk for the patient) are
reasons for transplantation under the pelvic peritoneum as com-
pared to the situation in the generally significantly atrophied ova-
ry.
The parietal peritoneum of the ovarian fossa is incised for this
purpose over a length of approximately 0.5–1 cm. A subperitoneal
pocket is created by blunt dissection and the tissue pieces are im-
planted in the pocket. The tissue pieces should preferably lie side
by side and not on top of each other (▶ Fig. 5). If the ovarian tissue
is to be taken once again (for example, if there is an increased risk
of a predisposition), the tissue should be marked, for example,
with titanium clips (▶ Fig. 6). Documentation of the site of trans-
plantation should be ensured.
Please refer to the corresponding literature in the case of trans-
plantation in/on the ovary [2, 27].
In general, it is not recommended to transplant all of the cryo-
preserved material at once but rather to implant only approxi-59
▶ Fig. 6 Marking the transplantation site with titanium clips.
GebFra Science | Reviewmately 1⁄3 to ½ of the available tissue in order to have tissue in re-
serve in the event of repeat loss of ovarian function [1]. However,
the patientʼs age in the case of an ovarian transplantation should
also be taken into account.
A natural pregnancy is possible in principle in the case of an or-
thotopic transplantation under the pelvic peritoneum. Therefore
in the case of an ovarian tissue transplantation, a fertility assess-
ment (tubal, uterine and extrauterine factors) and correction, if
necessary, should be performed [1]; that is, in the case of an ovar-
ian tissue transplantation, it is recommended to check the pa-
tency of the Fallopian tubes by means of “chromo”-pertubation
(with NaCl) and also to consider a hysteroscopy to rule out polyps,
myomas, adhesions or chronic endometritis. The transplantation
is performed on the side on which the tube is patent and the ana-
tomical conditions are the most favourable (▶ Fig. 7).
The risks of surgery are comparable to the risks in the case of
other laparoscopic procedures. Possible risks are secondary haem-
orrhage or a wound infection which occur in < 1% of cases [27–
29].(Chromo-)pe
Unilaterally oBilaterally patent?
Transplanta
patent
Transplantation on
right
▶ Fig. 7 Algorithm for selecting the transplantation side.
60JOINT DECISION
▪ The transplantation of ovarian tissue is performed laparo-
scopically.
▪ In the case of a transplantation, a “chromo”-pertubation
(for example, with NaCl) should be performed.
▪ Blunt preparation of a pocket is performed in the pelvic
peritoneum for this purpose and the ovarian tissue is in-
troduced into this pocket.
▪ If the ovarian tissue preparation is to be taken again later,
it is recommended to mark the transplantation site
(e.g. titanium clips).Follow-up Care of Patients Who
Have Undergone TransplantationWhat follow-up care should be provided?
The ovarian function can be restored in 80–85% of cases through
transplantations of ovarian tissue [15]. It takes between 2 to 6
months for the transplanted ovarian tissue to show signs of re-
sumption of its function (drop in FSH, rise in oestradiol) [48]. A
spontaneous pregnancy can be attempted if the tubes are patent
and there are no other relevant infertility factors. To increase the
likelihood of conception, the patient can be offered cycle moni-
toring with induction of ovulation through HCG within the frame-
work of intercourse at the optimal time. In the case of occluded
tubes or other infertility factors, assisted reproductive medicine
techniques (IVF; ICSI) must be used. If there is a high follicle den-
sity (antral follicle count and AMH), gonadotropin stimulation can
be considered, depending on the patientʼs age and the underlying
oncological disease, in order to accelerate conception, if applica-
ble. Alternatively, egg cells obtained in several spontaneous cycles
or stimulated cycles can also be vitrified so that an egg cell pool is
created for later use in an assisted reproductive medicine tech-
nique [52]. To increase the rate of implantation, particularly in
the case of whole-body radiation and radiation of the lesser pelvis,
other diagnostic measures, such as diagnostic endometrial proce-
dures to analyse the endometrial receptivity profile, can be of-
fered. After one year, approximately 2⁄3 of the transplants are stillrtubation
Bilaterally occluded?ccluded?
Transplantation on
right
tion on
side
Beckmann MW et al. Concept Paper on… Geburtsh Frauenheilk 2019; 79: 53–62
active. The tissue transplants which initially showed good activity
are generally active for several years. The mean length of ovarian
function after transplantation is about 4 to 7 years on average,
however this depends on the number of follicles in the ovarian tis-
sue and the age of the woman at the time of cryopreservation
[11]. If there are no signs of activity seen after approximately ½
year after transplantation, another transplantation of cryopre-
served ovarian tissue should be considered.
JOINT DECISION
▪ Patients with amenorrhoea should be offered a monthly
blood test (FSH, oestradiol, progesterone) 8–10 weeks
before the transplantation until signs of activity are de-
tected, and every two months, an ultrasound examination
should be offered.
▪ If there are signs of activity of the transplanted ovarian
tissue, it is recommended to perform cycle monitoring to
increase the chances of pregnancy, after other causes of
infertility have been clarified.
▪ In patients with causes of infertility (such as tubal infertili-
ty, reduced male fertility) ART measures must be taken.
▪ Patients who still had an active cycle prior to transplanta-
tion should be offered monthly cycle monitoring 8–10
weeks after the transplantation.
▪ Stimulation can be considered depending on the individual
situation (follicular density, number of attempts to con-
ceive, tumour entity).
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